Catalyst

Slingshot members are tracking this event:

AbbVie (ABBV) Phase 3 ENDURANCE-3 Data Evaluating Glecaprevir/Pibrentasvir in Difficult-to-Treat Genotype 3 HCV Patients Without Cirrhosis

Source Link:
https://news.abbvie.com/news/eight-weeks-treatment-with-abbvies-investigational-pan-genotypic-regimen-glecaprevirpibrentasvir-gp-achieved-high-svr12-rates-in-challenging-to-treat-genotype-3-chronic-hepatitis-c.htm

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ABBV
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Apr 21, 2017
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Endurance-3, Glecaprevir, Pibrentasvir, Difficult-to-treat, Genotype 3, International Liver Congress
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.